cagrilintide and semaglutide 2.4 mg Efficacy safety of co-administered once-weekly 2·4 with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Comparative Effectiveness of CagriSegma, Semaglutide,

Clinical trials have included both male and female participants, with some notable observations: Metabolic differences Men typically have higher baseline metabolic rates and different fat distribution patterns, which may influence response magnitude but not optimal dosing protocols

Ensuring Trimix is used within its beyond-use date helps prevent these adverse effects

A research study to look into the long-term effect on weight loss of CagriSema in people with obesity (NCT06780449) Summary: This is an ongoing Phase 3 trial (as of current knowledge) designed to evaluate the long-term efficacy and safety of once-weekly CagriSema in people living with obesity

Follow your provider's guidance